Survivin Expression in Patients with Non-Muscle-Invasive Urothelial Cell Carcinoma of the Bladder

Jose A. Karam, Yair Lotan, Raheela Ashfaq, Arthur I Sagalowsky, Shahrokh F. Shariat

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Objectives: Survivin is a member of the inhibitor of apoptosis gene family that controls mitotic progression and induces tumor cell invasion. Our objectives were to evaluate the association of survivin expression with the presence of urothelial cell carcinoma of the bladder and clinical outcomes in patients with non-muscle-invasive urothelial cell carcinoma of the bladder. Methods: Immunohistochemical staining for survivin was performed on archival bladder tissue microarray specimens from 9 normal controls and 74 consecutive patients who had Stage Ta, Tis, and/or T1 disease on transurethral resection (TUR). Staining was also performed on cystectomy specimens from 22 of these patients who had undergone radical cystectomy for disease progression. Survivin was considered overexpressed when more than 10% of the cells expressed survivin. Results: Survivin was not expressed in normal bladder urothelium. Survivin was overexpressed in 53% of non-muscle-invasive bladder tumors. Overexpression of survivin was associated with greater tumor grade (P <0.001). On multivariate analyses adjusted for the effects of TUR stage, grade, and intravesical therapy, survivin overexpression was independently associated with cancer recurrence (hazard ratio 2.50, 95% confidence interval 1.09 to 5.69, P = 0.02) and progression (hazard ratio 3.87, 95% confidence interval 1.13 to 13.24, P = 0.03), but not disease-specific survival (hazard ratio 1.88, 95% confidence interval 0.90 to 6.46, P = 0.07). A high concordance rate for survivin expression was found between the 22 matched TUR and cystectomy specimens (86%). Conclusions: Survivin expression analysis performed on TUR specimens might help identify patients with non-muscle-invasive urothelial cell carcinoma of the bladder at high risk of disease recurrence and progression who would benefit from closer follow-up or more aggressive therapy.

Original languageEnglish (US)
Pages (from-to)482-486
Number of pages5
JournalUrology
Volume70
Issue number3
DOIs
StatePublished - Sep 2007

Fingerprint

Urinary Bladder
Cystectomy
Carcinoma
Confidence Intervals
Disease Progression
Staining and Labeling
Recurrence
Urothelium
Neoplasms
Urinary Bladder Neoplasms
Multivariate Analysis
Apoptosis
Survival
Therapeutics
Genes

ASJC Scopus subject areas

  • Urology

Cite this

Survivin Expression in Patients with Non-Muscle-Invasive Urothelial Cell Carcinoma of the Bladder. / Karam, Jose A.; Lotan, Yair; Ashfaq, Raheela; Sagalowsky, Arthur I; Shariat, Shahrokh F.

In: Urology, Vol. 70, No. 3, 09.2007, p. 482-486.

Research output: Contribution to journalArticle

Karam, Jose A. ; Lotan, Yair ; Ashfaq, Raheela ; Sagalowsky, Arthur I ; Shariat, Shahrokh F. / Survivin Expression in Patients with Non-Muscle-Invasive Urothelial Cell Carcinoma of the Bladder. In: Urology. 2007 ; Vol. 70, No. 3. pp. 482-486.
@article{07347eac8a564342b86d3d0132177684,
title = "Survivin Expression in Patients with Non-Muscle-Invasive Urothelial Cell Carcinoma of the Bladder",
abstract = "Objectives: Survivin is a member of the inhibitor of apoptosis gene family that controls mitotic progression and induces tumor cell invasion. Our objectives were to evaluate the association of survivin expression with the presence of urothelial cell carcinoma of the bladder and clinical outcomes in patients with non-muscle-invasive urothelial cell carcinoma of the bladder. Methods: Immunohistochemical staining for survivin was performed on archival bladder tissue microarray specimens from 9 normal controls and 74 consecutive patients who had Stage Ta, Tis, and/or T1 disease on transurethral resection (TUR). Staining was also performed on cystectomy specimens from 22 of these patients who had undergone radical cystectomy for disease progression. Survivin was considered overexpressed when more than 10{\%} of the cells expressed survivin. Results: Survivin was not expressed in normal bladder urothelium. Survivin was overexpressed in 53{\%} of non-muscle-invasive bladder tumors. Overexpression of survivin was associated with greater tumor grade (P <0.001). On multivariate analyses adjusted for the effects of TUR stage, grade, and intravesical therapy, survivin overexpression was independently associated with cancer recurrence (hazard ratio 2.50, 95{\%} confidence interval 1.09 to 5.69, P = 0.02) and progression (hazard ratio 3.87, 95{\%} confidence interval 1.13 to 13.24, P = 0.03), but not disease-specific survival (hazard ratio 1.88, 95{\%} confidence interval 0.90 to 6.46, P = 0.07). A high concordance rate for survivin expression was found between the 22 matched TUR and cystectomy specimens (86{\%}). Conclusions: Survivin expression analysis performed on TUR specimens might help identify patients with non-muscle-invasive urothelial cell carcinoma of the bladder at high risk of disease recurrence and progression who would benefit from closer follow-up or more aggressive therapy.",
author = "Karam, {Jose A.} and Yair Lotan and Raheela Ashfaq and Sagalowsky, {Arthur I} and Shariat, {Shahrokh F.}",
year = "2007",
month = "9",
doi = "10.1016/j.urology.2007.05.009",
language = "English (US)",
volume = "70",
pages = "482--486",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Survivin Expression in Patients with Non-Muscle-Invasive Urothelial Cell Carcinoma of the Bladder

AU - Karam, Jose A.

AU - Lotan, Yair

AU - Ashfaq, Raheela

AU - Sagalowsky, Arthur I

AU - Shariat, Shahrokh F.

PY - 2007/9

Y1 - 2007/9

N2 - Objectives: Survivin is a member of the inhibitor of apoptosis gene family that controls mitotic progression and induces tumor cell invasion. Our objectives were to evaluate the association of survivin expression with the presence of urothelial cell carcinoma of the bladder and clinical outcomes in patients with non-muscle-invasive urothelial cell carcinoma of the bladder. Methods: Immunohistochemical staining for survivin was performed on archival bladder tissue microarray specimens from 9 normal controls and 74 consecutive patients who had Stage Ta, Tis, and/or T1 disease on transurethral resection (TUR). Staining was also performed on cystectomy specimens from 22 of these patients who had undergone radical cystectomy for disease progression. Survivin was considered overexpressed when more than 10% of the cells expressed survivin. Results: Survivin was not expressed in normal bladder urothelium. Survivin was overexpressed in 53% of non-muscle-invasive bladder tumors. Overexpression of survivin was associated with greater tumor grade (P <0.001). On multivariate analyses adjusted for the effects of TUR stage, grade, and intravesical therapy, survivin overexpression was independently associated with cancer recurrence (hazard ratio 2.50, 95% confidence interval 1.09 to 5.69, P = 0.02) and progression (hazard ratio 3.87, 95% confidence interval 1.13 to 13.24, P = 0.03), but not disease-specific survival (hazard ratio 1.88, 95% confidence interval 0.90 to 6.46, P = 0.07). A high concordance rate for survivin expression was found between the 22 matched TUR and cystectomy specimens (86%). Conclusions: Survivin expression analysis performed on TUR specimens might help identify patients with non-muscle-invasive urothelial cell carcinoma of the bladder at high risk of disease recurrence and progression who would benefit from closer follow-up or more aggressive therapy.

AB - Objectives: Survivin is a member of the inhibitor of apoptosis gene family that controls mitotic progression and induces tumor cell invasion. Our objectives were to evaluate the association of survivin expression with the presence of urothelial cell carcinoma of the bladder and clinical outcomes in patients with non-muscle-invasive urothelial cell carcinoma of the bladder. Methods: Immunohistochemical staining for survivin was performed on archival bladder tissue microarray specimens from 9 normal controls and 74 consecutive patients who had Stage Ta, Tis, and/or T1 disease on transurethral resection (TUR). Staining was also performed on cystectomy specimens from 22 of these patients who had undergone radical cystectomy for disease progression. Survivin was considered overexpressed when more than 10% of the cells expressed survivin. Results: Survivin was not expressed in normal bladder urothelium. Survivin was overexpressed in 53% of non-muscle-invasive bladder tumors. Overexpression of survivin was associated with greater tumor grade (P <0.001). On multivariate analyses adjusted for the effects of TUR stage, grade, and intravesical therapy, survivin overexpression was independently associated with cancer recurrence (hazard ratio 2.50, 95% confidence interval 1.09 to 5.69, P = 0.02) and progression (hazard ratio 3.87, 95% confidence interval 1.13 to 13.24, P = 0.03), but not disease-specific survival (hazard ratio 1.88, 95% confidence interval 0.90 to 6.46, P = 0.07). A high concordance rate for survivin expression was found between the 22 matched TUR and cystectomy specimens (86%). Conclusions: Survivin expression analysis performed on TUR specimens might help identify patients with non-muscle-invasive urothelial cell carcinoma of the bladder at high risk of disease recurrence and progression who would benefit from closer follow-up or more aggressive therapy.

UR - http://www.scopus.com/inward/record.url?scp=34648843747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34648843747&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2007.05.009

DO - 10.1016/j.urology.2007.05.009

M3 - Article

C2 - 17905101

AN - SCOPUS:34648843747

VL - 70

SP - 482

EP - 486

JO - Urology

JF - Urology

SN - 0090-4295

IS - 3

ER -